Loading organizations...
§ Private Profile · San Jose, CA, USA
NeuSpera Medical is a technology company.
NeuSpera Medical develops integrated sacral neuromodulation (iSNM) systems for treating urinary urge incontinence (UUI), a symptom of overactive bladder. Its core technology features an advanced, ultra-miniaturized neurostimulator implanted near the sacral nerve. Therapy is powered by a discreet, externally worn battery, enabling wireless charging and eliminating complications associated with fully implanted power sources.
NeuSpera Medical was founded in 2013 by Alexander J. Yeh, Ph.D. As a medical device innovator, Dr. Yeh's founding insight was to create millimeter-sized, battery-free implantable devices. This approach aimed to offer less invasive and more adaptable neuromodulation solutions for chronic conditions.
The company’s iSNM system serves patients with urinary urge incontinence seeking advanced treatment. Physicians utilize this system as a streamlined alternative to traditional sacral neuromodulation. NeuSpera Medical’s mission is to advance implantable medical device technology, improving the quality of life for individuals managing chronic illnesses.
NeuSpera Medical has raised $126.0M across 4 funding rounds.
NeuSpera Medical has raised $126.0M in total across 4 funding rounds.
NeuSpera Medical has raised $126.0M in total across 4 funding rounds.
NeuSpera Medical's investors include Creacion Ventures, Vertex Ventures, Treo Ventures, Vertex Ventures HC, 6 Dimensions Capital.
NeuSpera Medical has raised $126.0M across 4 funding rounds. Most recently, it raised $23.0M Series D in July 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2024 | $23M Series D | — | Creacion Ventures, Vertex Ventures | Announced |
| Jul 1, 2021 | $65M Series C | Treo Ventures, Vertex Ventures HC | Creacion Ventures, Vertex Ventures | Announced |
| Feb 1, 2019 | $12M Series B | — | Creacion Ventures, Vertex Ventures | Announced |
| Jan 1, 2018 | $26M Series B | 6 Dimensions Capital | Creacion Ventures, Vertex Ventures | Announced |
Neuspera Medical is a medtech company developing minimally invasive implantable neurostimulation devices, with its flagship product being the first FDA-approved integrated sacral neuromodulation (iSNM) system for treating urinary urge incontinence (UUI), a key symptom of overactive bladder (OAB).[1][2][4] The system features an ultra-miniaturized, battery-free implant near the sacral nerve, powered by a discreet external wearable charger, delivering therapy comparable to traditional SNM while eliminating implanted battery risks and complications.[1][3][4] It serves patients, primarily women (affecting 1 in 5 in the U.S.), frustrated by unpredictable UUI episodes that disrupt daily life, offering a patient-centered, less invasive alternative that fits seamlessly into lifestyles.[1][4]
The company solves the problem of ineffective or burdensome OAB treatments by providing accessible, comfortable neuromodulation with directional energy adaptation for deep-body implants, backed by $23 million in Series D funding in 2024 to reach FDA approval, achieved in June 2025.[1][3][4] Growth momentum includes FDA clearance for chronic peripheral nerve pain earlier and full UUI approval, positioning Neuspera for U.S. commercialization amid rising demand for advanced OAB therapies.[3][4]
Neuspera Medical emerged from the vision of Alexander J. Yeh, its founder, Chief Technology Officer, and VP of Research & Development, a medical device innovator focused on transforming millimeter-sized wireless implants into practical tools for patient care.[2] The idea stemmed from advancing directionally adaptive energy systems to power tiny deep-body implants, starting with sacral neuromodulation for UUI.[1][2] Key leadership includes Dave, a 30-year medtech veteran and CEO who scaled Ivantis from early employee to $475 million acquisition by Alcon after FDA approval and global sales; and Steve, a commercial expert who grew Vertos Medical's revenue from $10 million to $80 million before its Stryker acquisition.[2]
Pivotal early traction came via $23 million Series D financing in July 2024, led by Vertex Ventures HC and Treo Ventures, funding through FDA premarket approval.[3] This built on prior FDA clearance for chronic pain, culminating in June 2025 UUI approval—the first for an integrated SNM system—marking a breakthrough from investigational device to market-ready therapy.[3][4]
Neuspera rides the neuromodulation wave in medtech, targeting the growing OAB market where UUI affects 1 in 5 U.S. women, driving demand for less invasive alternatives to drugs or traditional SNM with bulky implants.[1][4] Timing aligns with 2025 FDA approval amid post-pandemic focus on quality-of-life therapies for chronic conditions, fueled by miniaturization advances in wireless power and implants.[1][2][4] Market forces like aging populations, reimbursement expansions, and investor interest (e.g., Series D from medtech VCs) favor discreet, efficacious devices that reduce surgical risks.[3]
The company influences the ecosystem by pioneering iSNM, potentially expanding sacral neuromodulation access and inspiring battery-free platforms for pain, neurology, and beyond, challenging incumbents with patient-preferred form factors.[1][3]
Neuspera is poised for U.S. launch and revenue ramp post-2025 FDA approval, leveraging its validated efficacy to capture OAB share from legacy SNM providers.[4] Trends like AI-optimized stimulation, further miniaturization, and global expansion (building on pain clearance) will shape growth, with platform adaptability opening pipelines for new indications.[1][2] Influence may evolve from UUI disruptor to neuromodulation leader, as team track record suggests scalable adoption and potential acquisition.
This positions Neuspera as a patient-empowering medtech innovator, reclaiming lives from OAB's frustrations through uncompromised, lifestyle-fitting therapy.[1]